BCM
FBLG icon

Bridgeway Capital Management’s FibroBiologics FBLG Stock Holding History

Bridgeway Capital Management’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,000
Closed -$24.9K – 1293
2025
Q2 		$24.9K Sell
2,000
-1,750
-47% -$31.6K ﹤0.01% 1156
2025
Q1 		$67.5K Buy
3,750
+2,500
+200% +$71.4K ﹤0.01% 1099
2024
Q4 		$50K Hold
1,250
– – ﹤0.01% 1156
2024
Q3 		$77.3K Buy
+1,250
New +$83.1K ﹤0.01% 1178

Other funds holding FBLG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LM
Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return
YAG
Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bridgeway Capital Management's FBLG Position: Q3 2025 in Review

Bridgeway Capital Management sold out of FibroBiologics (FBLG) in Q3 2025, closing a stake of 2,000 shares — an estimated $24.9K sold.

Bridgeway Capital Management first reported a position in FBLG in Q3 2024 and held it in 4 quarters. The position peaked at $77.3K in Q3 2024. 52 funds tracked by Wall St. Rank hold FBLG as of Q3 2025.

  • Bridgeway Capital Management reported no remaining FibroBiologics position as of Q3 2025 after selling out during the quarter.
  • Bridgeway Capital Management sold 2,000 FibroBiologics shares in Q3 2025, an estimated $24.9K.
  • Bridgeway Capital Management first reported a position in FibroBiologics in Q3 2024 and held it in 4 quarters.
  • Bridgeway Capital Management's FibroBiologics position peaked at $77.3K in Q3 2024.
  • 52 funds tracked by Wall St. Rank held FibroBiologics as of Q3 2025.

Based on Bridgeway Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.